Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients?

References

• Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 2019;21:v1–100.
   PubMed Web of Science ®Google Scholar
• Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP. Glioblastoma in England: 2007–2011. Eur J Cancer 2015;51:533–42.
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Kumabe T, Watanabe M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir 2009;151:1349–58.
   PubMed Web of Science ®Google Scholar
• Walid MS. Prognostic factors for long-term survival after glioblastoma. Perm J 2008;12:45–8. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3037140&tool=pmcentrez&rendertype=abstract.
   PubMedGoogle Scholar
• Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012;38:271–91.
   PubMed Web of Science ®Google Scholar
• Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015;129:829–48.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Fabian D, Guillermo Prieto Eibl M, Alnahhas I, et al. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers 2019;11:174.
   PubMed Web of Science ®Google Scholar
• Kirson ED, Dbalý V, Tovaryš F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 2007;104:10152–7.
   PubMed Web of Science ®Google Scholar
• Thomas AA, Rauschkolb PK. Tumor treating fields for glioblastoma: should it or will it ever be adopted? Curr Opin Neurol 2019;32:857–63.
   PubMed Web of Science ®Google Scholar
• Weinberg U. Novocure’s tumor treating fields: innovative brain cancer therapy with survival and safety benefits. Nature Outlook 2018.
   Google Scholar
• Kim EH, Jo Y, Sai S, et al. Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. Oncogene 2019;38:6630–46.
   PubMed Web of Science ®Google Scholar
• Kessler A, Linsenmann T, Westermaier T, et al. P01.046 Complete radiological response under treatment with tumor treating fields following subtotal resection in a series of three Glioblastoma patients. Neuro Oncol 2018;20:iii239.
   Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. J Am Med Assoc 2017;318:2306–16.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial. J Am Med Assoc 2015;314:2535–43.
   PubMed Web of Science ®Google Scholar
• Clark PA, Gaal JT, Strebe JK, et al. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. J Clin Neurosci 2017;36:120–4.
   PubMed Web of Science ®Google Scholar
• Giladi M, Munster M, Schneiderman RS, et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol 2017;12:1–13.
   PubMed Web of Science ®Google Scholar
• NICE (National Institute for Health and Care Excellence). Brain tumours (primary) and brain metastases in adults | Evidence reviews for the investigation, management and follow-up of glioma. NICE; 2018.
   Google Scholar
• Kelly C, Majewska P, Ioannidis S, Raza MH, Williams M. Estimating progression-free survival in patients with glioblastoma using routinely collected data. J Neurooncol 2017;135:621–7.
   PubMed Web of Science ®Google Scholar
• Kanner AA, Wong ET, Villano JL, Ram Z. Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician’s choice chemotherapy (Seminars in Oncology (2014) 41:5 (S25–S34)). Semin Oncol 2015;42:e56–e66.
   Google Scholar
• Radke J, Koch A, Pritsch F, et al. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. Acta Neuropathol Commun 2019;7:89.
   PubMed Web of Science ®Google Scholar
• Sagberg LM, Solheim O, Jakola AS. Quality of survival the 1st year with glioblastoma: a longitudinal study of patient-reported quality of life. J Neurosurg 2016;124:989–97.
   PubMed Web of Science ®Google Scholar
• Minniti G, Scaringi C, Baldoni A, et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys 2013;86:285–91.
   PubMed Web of Science ®Google Scholar
• Onken J, Goerling U, Heinrich M, et al. Patient reported outcome (PRO) among high-grade glioma patients receiving TTFields treatment: a two center observational study. Front Neurol 2019;10:1026.
   PubMed Web of Science ®Google Scholar
• Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol 2019;141:467–73.
   PubMed Web of Science ®Google Scholar
• Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48:2192–202.
   PubMed Web of Science ®Google Scholar
• Lazaridis L, Schäfer N, Teuber S, Tobias H, Teresa B. Tumour treating fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. J Cancer Res Clin Oncol 2020;146:787–92.
   PubMed Web of Science ®Google Scholar
• Kinzel A, Ambrogi M, Varshaver M, Kirson ED. ED. Tumor treating fields for glioblastoma treatment: patient satisfaction and compliance with the second-generation Optune® system. Clin Med Insights Oncol 2019;13:117955491882544–6.
   Web of Science ®Google Scholar
• Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2016;18:1129–36.
   PubMed Web of Science ®Google Scholar
• Messali A, Hay JW, Villacorta R. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol 2013;15:1532–42.
   PubMed Web of Science ®Google Scholar
• Martikainen JA, Kivioja A, Hallinen T, Vihinen P. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. Pharmacoeconomics 2005;23:803–15.
   PubMed Web of Science ®Google Scholar
• Garside R, Pitt M, Anderson R. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 2007;11:1–258.
   Web of Science ®Google Scholar
• Zhang I, Knisely JPS. Tumor treating fields-effective, but at what cost? Transl Cancer Res 2016;5:S1349–S53.
   Web of Science ®Google Scholar